Your browser doesn't support javascript.
loading
A disease-specific iPS cell resource for studying rare and intractable diseases.
Saito, Megumu K; Osawa, Mitsujiro; Tsuchida, Nao; Shiraishi, Kotaro; Niwa, Akira; Woltjen, Knut; Asaka, Isao; Ogata, Katsuhisa; Ito, Suminobu; Kobayashi, Shuzo; Yamanaka, Shinya.
Afiliação
  • Saito MK; Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, 6068507, Japan. msaito@cira.kyoto-u.ac.jp.
  • Osawa M; Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, 6068507, Japan.
  • Tsuchida N; Clinical Research Center, National Hospital Organization Headquarters, Tokyo, 1528621, Japan.
  • Shiraishi K; Information Security Office, Center for iPS Cell Research and Application, Kyoto University, Kyoto, 6068507, Japan.
  • Niwa A; Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, 6068507, Japan.
  • Woltjen K; Department of Life Science Frontiers, Center for iPS Cell Research and Application, Kyoto University, Kyoto, 6068507, Japan.
  • Asaka I; Department of Fundamental Cell Technology, Center for iPS Cell Research and Application, Kyoto University, Kyoto, 6068507, Japan.
  • Ogata K; National Hospital Organization Higashisaitama National Hospital, Hasuda, 3490196, Japan.
  • Ito S; Clinical Research Center, National Hospital Organization Headquarters, Tokyo, 1528621, Japan.
  • Kobayashi S; Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura, 2478533, Japan.
  • Yamanaka S; Department of Life Science Frontiers, Center for iPS Cell Research and Application, Kyoto University, Kyoto, 6068507, Japan.
Inflamm Regen ; 43(1): 43, 2023 Sep 08.
Article em En | MEDLINE | ID: mdl-37684663
BACKGROUND: Disease-specific induced pluripotent stem cells (iPSCs) are useful tools for pathological analysis and diagnosis of rare diseases. Given the limited available resources, banking such disease-derived iPSCs and promoting their widespread use would be a promising approach for untangling the mysteries of rare diseases. Herein, we comprehensively established iPSCs from patients with designated intractable diseases in Japan and evaluated their properties to enrich rare disease iPSC resources. METHODS: Patients with designated intractable diseases were recruited for the study and blood samples were collected after written informed consent was obtained from the patients or their guardians. From the obtained samples, iPSCs were established using the episomal method. The established iPSCs were deposited in a cell bank. RESULTS: We established 1,532 iPSC clones from 259 patients with 139 designated intractable diseases. The efficiency of iPSC establishment did not vary based on age and sex. Most iPSC clones originated from non-T and non-B hematopoietic cells. All iPSC clones expressed key transcription factors, OCT3/4 (range 0.27-1.51; mean 0.79) and NANOG (range 0.15-3.03; mean 1.00), relative to the reference 201B7 iPSC clone. CONCLUSIONS: These newly established iPSCs are readily available to the researchers and can prove to be a useful resource for research on rare intractable diseases.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article